Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Pharma
FDA revokes approval of Oncopeptides' Pepaxto
Following an FDA request for withdrawal of Oncopeptides’ multiple myeloma drug Pepaxto from the U.S. market in late 2022, the other shoe has dropped.
Fraiser Kansteiner
Feb 23, 2024 11:10am
Theravance's COPD med Yupelri flunks head-to-head study
Jan 5, 2024 10:14am
An Imbruvica combo regimen could have a new future in MCL
Dec 12, 2023 12:33pm
Bayer's corporate overhaul faces new questions after trial flop
Nov 21, 2023 4:37pm
Apellis counters Izervay results with long-term data of its own
Nov 6, 2023 3:53pm
Catalent faces new possible 'cliff' after Sarepta miss: analyst
Nov 1, 2023 8:50am